Biotech · Private company · Portland, OR, US
Aronora, Inc.
Track this companyFree. Adds Aronora, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- AB002 Dose 1Phase 2 · End Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AB002 Dose 2Phase 2 · End Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AB023- Dose 1Phase 2 · End Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AB023-Dose 2Phase 2 · End Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- E-WE Thrombin- Dose 1Phase 1 · ThrombosisClinicalTrials.gov · fetched Nov 12, 2026
- E-WE Thrombin- Dose 2Phase 1 · ThrombosisClinicalTrials.gov · fetched Nov 12, 2026
- E-WE Thrombin- Dose 3Phase 1 · ThrombosisClinicalTrials.gov · fetched Nov 12, 2026
- E-WE Thrombin- Dose 4Phase 1 · ThrombosisClinicalTrials.gov · fetched Nov 12, 2026
- xisomab 3G3- Dose 1Phase 1 · ThrombosisClinicalTrials.gov · fetched Nov 12, 2026
- xisomab 3G3- Dose 4Phase 1 · ThrombosisClinicalTrials.gov · fetched Nov 12, 2026
- xisomab 3G3-Dose 2Phase 1 · ThrombosisClinicalTrials.gov · fetched Nov 12, 2026
- xisomab 3G3-Dose 3Phase 1 · ThrombosisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic HemodialysisPHASE2 · COMPLETED · started Jul 3, 2019ClinicalTrials.gov NCT03963895 · fetched Nov 12, 2026
- Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic HemodialysisPHASE2 · COMPLETED · started Oct 29, 2018ClinicalTrials.gov NCT03612856 · fetched Nov 12, 2026
- Safety and Tolerability Study of E-WE Thrombin in Healthy Adult SubjectsPHASE1 · COMPLETED · started May 30, 2018ClinicalTrials.gov NCT03453060 · fetched Nov 12, 2026
- Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult SubjectsPHASE1 · COMPLETED · started Jun 5, 2017ClinicalTrials.gov NCT03097341 · fetched Nov 12, 2026
NIH awards6
- Contact Pathway Inhibitor to Prevent Catheter-Related ThrombosisFiscal year 2026 · $1.1MNIH RePORTER 5R44HL170881-03 · fetched Nov 12, 2026
- Contact Pathway Inhibitor to Prevent Catheter-Related ThrombosisFiscal year 2025 · $1.1MNIH RePORTER 4R44HL170881-02 · fetched Nov 12, 2026
- Contact Pathway Inhibitor to Prevent Vascular Access FailureFiscal year 2025 · $1.3MNIH RePORTER 5R44HL167467-03 · fetched Nov 12, 2026
- Contact Pathway Inhibitor to Prevent Catheter-Related ThrombosisFiscal year 2024 · $494KNIH RePORTER 1R44HL170881-01A1 · fetched Nov 12, 2026
- Contact Pathway Inhibitor to Prevent Vascular Access FailureFiscal year 2024 · $1.5MNIH RePORTER 4R44HL167467-02 · fetched Nov 12, 2026
- Thrombopoietin Targeting in Myeloproliferative NeoplasmsFiscal year 2024 · $669.1KNIH RePORTER 5R44HL162386-03 · fetched Nov 12, 2026